ReviewFrontiers in pharmacology2025
Modulating TRPV1 and TRPA1 channels: a viable strategy for treating asthma using Chinese herbal medicines.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Terpenes and terpenoids modulating TRPV channels in diabetes: role in fibrosis and inflammatory signaling.Molecular biology reports · 2026Review
- Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.Dermatology and therapy · 2026Review
- Review
- Cinnamon-Derived Phytonutrients as Modulators of Ion Channels and G Protein-Coupled Receptor Signaling in Metabolic Diseases.Nutrients · 2026Review
- pH sensing and inflammation: linking acidic microenvironments to immune reprogramming.Frontiers in immunology · 2026Review
- Mechanically induced dysregulation of calcium homeostasis: a molecular linchpin in asthmatic pathogenesis.European journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma represents a significant global health challenge, imposing a substantial burden on society worldwide. Over the past decades, the development of asthma medications has significantly reduced asthma-related mortality. However, current pharmacological treatment regimens have not yet demonstrated the capacity to induce a durable remission of asthma. Transient receptor potential channels, specifically vanilloid receptor 1 (TRPV1) and ankyrin 1 (TRPA1), are polymodal sensory channels extensively distributed in the lungs and represent promising therapeutic targets for asthma. Increasing evidence suggests that Chinese herbal medicines (CHM) exert beneficial effects in asthma treatment by modulating TRPV1/TRPA1. Therefore, this study systematically analyzed 134 articles covering the pathogenesis of asthma, current treatment strategies, the role of TRPV1/TRPA1 in asthma, and the modulation of TRPV1/TRPA1 by Chinese herbal medicines in asthma. In summary, our review comprehensively elaborates on how CHM modulates TRPV1/TRPA1 channels to alleviate pulmonary inflammation. These findings provide viable options for asthma drug discovery and establish the foundation for developing effective CHM-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.